Global Transcriptomics Technologies Market Size to grow USD 19514 Million by 2030 | CAGR of 17% – Yahoo Finance

The Global Transcriptomics Technologies Market Size was valued at USD 4,750 Million in 2021 and the worldwide transcriptomics technologies market is expected to reach USD 19,514 Million by 2030, according to a research report published by Spherical Insights & Consulting. Companies Covered: Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., QIAGEN, Thermo Fisher Scientific, Inc., Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Inc., Pacific Bioscience of California, Inc., Affymetrix, Inc., Danaher Corp., and Promega and others 20+ prominent key players we have added in the final report. Global Economy: Recession Risk Rising Analysis and Russia-Ukraine Conflict War Impact we have added in the report.
New York, United States, Nov. 17, 2022 (GLOBE NEWSWIRE) — The Global Transcriptomics Technologies Market Size to grow from USD 4,750 million in 2021 to USD 19,514 million by 2030, at a Compound Annual Growth Rate (CAGR) of 17% during the forecast period. The transcriptomics technologies market has grown due to growing government funding because of the rise in demand for RNA sequencing.  In addition, the government bodies are also giving approval to the market players.
Get a Sample PDF Brochure: https://www.sphericalinsights.com/request-sample/1300  
The next-generation sequencing segment to account for the largest market size during the forecast period
Based on the technology, the global transcriptomics technologies market is categorized into Microarrays, PCR, Gene Regulation Technologies, and Next Generation Sequencing. The next-generation sequencing segment to account for the largest market size during the forecast period. Recent technological advances like sample multiplexing, complete genome coverage, higher sensitivity, and simultaneous broad genome sequencing have all helped this market segment grow. In genomic research, the sequencing method called “next-generation sequencing” (NGS) is being used more and more. Researchers can use genome sequencing in a wider range of ways to study cells that it is both affordable and of high quality. This helps them learn more about how the genome and transcriptome work.
The drug discovery and research segment to hold a higher CAGR during the forecast period.
Based on application, the transcriptomics technologies market is categorized into Clinical Diagnostics, Drug Discovery and Research, Bioinformatics, and Comparative Transcriptomics. The drug discovery and research segment to hold a higher CAGR during the forecast period. Compared to traditional RNA-sequencing methods, the field of transcriptomics, which includes single-cell RNA-sequencing (scRNA-seq) and high-plex imaging, has a lot of technological advances that make it easier to find biomarkers and new drugs. This is true because both of these methods are used in transcriptomics. High throughput methods needed to find therapeutic targets so drug development can move forward could help the market grow.
Browse key industry insights spread across 198  pages with 108  market data tables and figures & charts from the report “Global Transcriptomics Technologies Market Size, Share, and COVID-19 Impact Analysis, By Technology (Microarrays, PCR, Gene Regulation Technologies, and Next Generation Sequencing), By Application (Clinical Diagnostics, Drug Discovery and Research, Bioinformatics and Comparative Transcriptomics), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030”, in detail along with the table of contents.
Buy Now Full Report: https://www.sphericalinsights.com/checkout/1300  
The COVID-19 pandemic has made an adverse impact on credit portfolios. There has been an unprecedented rise in unemployment and disruption in economic activity, putting a strain on the solvency of customers and companies. Central banks have taken a proactive approach by injecting liquidity into the market by lowering interest rates and asset purchase programs. Managing and monitoring credit, market, liquidity, and operational risk across financial markets were hard enough with ongoing geopolitical tensions, international trade wars, and the occasional hurricanes and earthquakes. The current pandemic situation has forced chief risk officers and their teams to recalibrate old assumptions and models used to manage and monitor risk. COVID-19’s global impact has shown that interconnectedness plays an important role in international cooperation. As a result, many governments started rushing toward identifying, evaluating, and procuring reliable solutions powered by AI.
North America is estimated to account for the highest market share in 2021.
The Global Transcriptomics Technologies Market has been segmented into five major regions:  North America, Europe, Asia-Pacific, South America, The Middle East and Africa. North America is expected to be the largest market. In North America, the market for transcriptomics is driven by the growing need for new treatment options in research, diagnostics, and synthetic biology. The number of people with cancer, infectious diseases, and chronic diseases is also rising. Most of this demand is coming from well-known pharmaceutical companies. In the United States, the growing demand for RNA-based NGS is driving the market for transcriptomics. Asia Pacific to hold a higher CAGR during the forecast period.
Inquire Before Buying This Research Report: https://www.sphericalinsights.com/inquiry-before-buying/1300  
Key Companies & Recent Developments: The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market. Major vendors in the Global Transcriptomics technologies Market include Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., QIAGEN, Thermo Fisher Scientific, Inc., Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Inc., Pacific Bioscience of California, Inc., Affymetrix, Inc., Danaher Corp., and Promega Agilent Technologies, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., QIAGEN, Thermo Fisher Scientific, Inc., Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Inc., Pacific Bioscience of California, Inc., Affymetrix, Inc., Danaher Corp., and Promega and others 20+ prominent key players we have added in the final report. Global Economy: Recession Risk Rising Analysis and Russia-Ukraine Conflict War Impact we have added in the report.
Some of the Key Developments:
In May 2022, BioSkryb Genomics first announced the Early Access Program (EAP) for ResolveOME. With this one-cell process, the whole genome and full-length mRNA transcripts of the whole transcriptome can be amplified from a single cell.
In January 2022, Parse Biosciences, a company that helps researchers with single-cell sequencing, made a deal with Research Instruments Ptv Ltd to sell Parse’s Evercore Whole Transcriptome Kits (WTKs), Cell Fixation Kits, and Nuclei Fixation Kits in Singapore and the rest of Southeast Asia.
Discount Price @ https://www.sphericalinsights.com/request-discount/1300
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Follow Us: LinkedIn | Facebook | Twitter

Will there be a new beginning?
‘Rich Dad Poor Dad’ is sounding the alarm — again.
Given CEO Warren Buffett's straightforward investing advice and a long track record of huge returns, it's not surprising that investors closely follow Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) every move. Berkshire's most surprising purchase in the third quarter was Taiwan Semiconductor Manufacturing (NYSE: TSM), the world's largest microchip manufacturer.
The chief investment strategist at Charles Schwab recommends investors look beyond broad categories of value or growth. "This is time you want to look for great companies without putting blinders on."
House Democrats have proposed legislation that could end Trump tax cuts for the wealthy and corporations. If passed, this could implement some of the biggest tax increases in decades. But while these tax changes aim to make good on President … Continue reading → The post Tax the Rich: Biden to End Trump Tax Cuts on the Wealthy appeared first on SmartAsset Blog.
Oil stocks have taken a victory lap throughout 2022. Surging commodity prices are bolstering profits at a time when many companies are getting hit with inflation and softening demand. ExxonMobil (NYSE: XOM), Enbridge (NYSE: ENB), and Diamondback Energy (NASDAQ: FANG) each not only pay a dividend but have beaten the S&P 500 over the past year.
2023 could be a big year for both Nio and Rivian, but one EV stock could rebound faster in the near term.
The emerging picture of what went wrong suggests the crypto empire was a mess almost from the start, with few boundaries, financial or personal.
All the top market indices fell into bear market territory on multiple occasions this year. While the market is still down, long-term investors might want to take advantage of some discounted pricing — particularly for dividend stocks. Since dividend yields have an inverse relationship with pricing, there are plenty of high-quality dividend stocks trading at stock prices creating yields 3 to 6 times higher than the average S&P 500 stock.
Generation Investment exited its investment in Intel, reduced stakes in Shopify and Microsoft, and bought more Twilio shares in the third quarter.
In much of 2020 and 2021, a mention of "Robinhood stocks" may have conjured up images of meme stocks that were making insane — and mostly short-lived — gains in the market. Now investors that use the Robinhood Markets (NASDAQ: HOOD) online trading platform appear to be shifting their focus to more stable companies, likely as the broad market sell-off of the past year caused many investors to take a more cautious approach to where they put their remaining money. For investors looking for a few great companies to give further consideration to from the current list of most popular stocks among Robinhood users, look no further than Tesla (NASDAQ: TSLA), Amazon (NASDAQ: AMZN), and Apple (NASDAQ: AAPL).
Pfizer (NYSE: PFE) nearly doubled its revenue last year by pulling in $81.3 billion, second only to Johnson & Johnson among pharmaceutical companies. Now that Pfizer is trading at a little more than nine times earnings, might it be a good entry point for investors? Pfizer trades for roughly $81 a share because investors expect the company's revenue to fall back to its 2020 level of $41.9 billion.
In this article, we will take a look at billionaire Steve Cohen’s top dividend stocks. If you want to see more of billionaire Steve Cohen’s top dividend stocks, go directly to Billionaire Steve Cohen’s Top 5 Dividend Stocks. Billionaire Steve Cohen is the founder of Point72 Asset Management which as of the end of September […]
The implosion, within a few days, of the FTX cryptocurrency exchange is a financial fiasco which has not yet revealed all its implications, collateral damage and accountabilities. FTX is a company which was valued at $32 billion in February and had emerged as the savior of crypto firms weakened by the credit crunch caused by the collapse of sister cryptocurrencies Luna and UST, or TerraUSD, in May. The firm, that was the centerpiece of 30-year-old Sam Bankman-Fried's crypto empire, was considered one of the most influential and financially solid players in the cryptocurrency industry.
The market is down. But your portfolio doesn’t have to be.
The market rally faces key resistance, namely the S&P 500 nearing the 200-day line. So is tech titan Apple stock.
Many high-yield dividend stocks come with significant trade-offs that make them less attractive to investors. Here are four fantastic dividend stocks with yields of 4% or more. Devon Energy (NYSE: DVN) offers a unique dividend consisting of two parts: a fixed component and a variable component.
With just about six weeks left in the year, Warren Buffett's company Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B) looks poised to soundly beat the broader market in 2022. Over its long and storied history, Berkshire has a strong track record of beating the market, and Buffett is considered one of the greatest investors of all time, so it's always a good idea to keep an eye on the company's portfolio. With that said, here are two no-brainer Buffett stocks to buy for 2023.
In this article we are going to estimate the intrinsic value of Alphabet Inc. ( NASDAQ:GOOGL ) by estimating the…
Using technical analysis of the charts of those stocks, and, when appropriate, recent actions and grades from TheStreet's Quant Ratings, we zero in on three names. While we will not be weighing in with fundamental analysis, we hope this piece will give investors interested in stocks on the way down a good starting point to do further homework on the names. Alarm.com Holdings Inc. recently was downgraded to Hold with a C rating by TheStreet's Quant Ratings.

source